Publications by authors named "Robert M Day"

Claim this Profile
A
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Mamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, Shinichi Imafuku, Robert M Day

J Dermatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Jeffrey Crowley, Diamant Thaçi, Pascal Joly, Ketty Peris, Kim A Papp, Robert M Day

J Am Acad Dermatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Robert Bissonnette, David M Pariser, Norman R Wasel, Joana Goncalves, Robert M Day

J Am Acad Dermatol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Jeffrey M Sobell, Peter Foley, Darryl Toth, Ulrich Mrowietz, Giampiero Girolomoni, Robert M Day

Acta Derm Venereol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Phoebe Rich, Melinda Gooderham, Hervé Bachelez, Joana Goncalves, Robert M Day

J Am Acad Dermatol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Kim Papp, Kristian Reich, Craig L Leonardi, Leon Kircik, Sergio Chimenti, Robert M Day

J Am Acad Dermatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Alice B Gottlieb, Robert T Matheson, Alan Menter, Craig L Leonardi, Robert M Day

J Drugs Dermatol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.
Peter H Schafer, Robert M Day

J Am Acad Dermatol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Vibeke Strand, David Fiorentino, ChiaChi Hu, Robert M Day, Randall M Stevens

Health Qual Life Outcomes· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Kim Papp, Jennifer C Cather, Les Rosoph, Howard Sofen, Richard G Langley, Robert M Day

Lancet· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis